There’s little doubt in my mind that NP’s bet regarding a $5 SP point in the coming months is based on TNBC results and more specifically the CTC results. If the delay in starting the TNBC trial was truly to ensure that the CTC results are irrefutable, I’m fine with that, as a potential cure to TNBC deaths, or at least a significant prolongation of life, will put CYDY at an entirely new level of value that is hard to put a price on.
I have been adding more shares here at the .38-.40 level, averaging down nicely from my initial purchases in 2015. I have a plan to recoup my initial investment and take profits at different levels once CYDY starts climbing and I hope others do as well. I’ll have a decent amount of shares remaining after profit taking to make an excellent return in the long run as leronlimab hopefully works for other indications.